Expand BLTE Menu
BLTE MENU

BLTE Latest Press Releases

-- September 8, 2026 --

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 6:00 AM

-- September 1, 2026 --

Belite Bio to Participate in Four Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 24, 2026 --

Belite Bio to Host Virtual Commercial Day on September 2, 2026 Globe Newswire 4:00 PM

-- August 21, 2026 --

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Globe Newswire 8:00 AM

-- August 12, 2026 --

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 9:45 PM

-- August 11, 2026 --

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 4:01 PM

-- August 6, 2026 --

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- July 20, 2026 --

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 Globe Newswire 8:00 AM

-- July 15, 2026 --

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference Globe Newswire 8:00 AM

-- July 6, 2026 --

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium Globe Newswire 8:00 AM
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Globe Newswire 7:00 AM

-- June 12, 2026 --

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 9:30 PM

-- June 2, 2026 --

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 8:00 AM

-- May 20, 2026 --

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 6:00 AM

-- May 18, 2026 --

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland Globe Newswire 4:00 PM

-- May 15, 2026 --

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) Globe Newswire 8:00 AM

-- May 13, 2026 --

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results Globe Newswire 4:00 PM

-- April 29, 2026 --

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing Globe Newswire 8:44 AM

-- April 27, 2026 --

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit Globe Newswire 8:00 AM

-- April 23, 2026 --

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026 Globe Newswire 8:35 AM
Belite Bio to Participate in Four Upcoming Investor Conferences Globe Newswire 8:00 AM

-- April 22, 2026 --

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th Globe Newswire 8:35 AM

-- April 21, 2026 --

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Globe Newswire 4:00 PM
Market Data Delayed 15 Minutes